RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small C…
この記事を読む
記事一覧 16ページ
この記事を読む
EGFR-TKI耐性後の免疫治療 vs 殺細胞性抗がん剤
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EG…
この記事を読む
MET14skippingのテポチニブ治療は背景に依存するか
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION…
この記事を読む
SP142と22C3:同じか異なるのか
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell L…
この記事を読む
EGFR遺伝子変異陽性、切除後の予後は
Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM…
この記事を読む
EGFR遺伝子変異陽性の術後補助化学療法の層別化
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small C…
この記事を読む
腫瘍サイズと免疫チェックポイント阻害薬
The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with …
この記事を読む
EGFR遺伝子変異陽性、手術追加の意義は？
Thoracic surgery improved overall survival in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung a…
この記事を読む
非扁平上皮癌の方がPD-L1発現とOSが相関しやすい？
Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Non…
この記事を読む
アファチニブ→オシメルチニブの治療シークエンス
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-inter…